Latest Content

BPL-003 phase 2a part 2 results show reductions in depression symptoms.

A new US Department of War backed phase 2a study will test BXCL501's efficacy in easing acute stress reactions and preventing PTSD.

Stroke recovery lasts years; learn why fatigue, sleep, hormones and cognition demand ongoing rehab beyond 90 days—and how progress can continue.

Experts share how roluperidone provides a new opportunity in the schizophrenia treatment landscape.

Early MRS data show AL001 delivers lithium effects across the brain while sparing glutamate, hinting at better tolerability than lithium carbonate.

How is artificial intelligence affecting human intelligence?

Remembering 2 child and adolescent psychiatrists...

Should hospitals be required to integrate AI-driven risk stratification into emergency department workflows to maintain accreditation? Join the debate.

As Canada approaches the planned implementation of their medical euthanasia program for patients with sole psychiatric illnesses, these authors make an argument as to why euthanasia should remain closed to patients with psychiatric disorders.

What are the cultural, religious, philosophical, and psychological factors that differentiate Eastern and Western values regarding assisted suicide and euthanasia?

New analysis links traumatic brain injury to later psychosis, prompting long-term screening and follow-up.

Often the best opportunities for mental health growth come when psychiatry, religions, and spirituality can enhance one another.

A novel form of agomelatine shows positive initial results.